⌕
Olema Oncology · OLMA · Nasdaq
Tenet 55 · Mixed
Compare
$7.36−2.65%At closeTenet 55 · Mixed
$7.36−0.20 (−2.65%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Olema Oncology (OLMA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+120.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼25.5%
−162.5
FY21→FY25CAGR —
Free cash flow ($M)▼40.4%
−146.7
FY21→FY25CAGR —
Diluted EPS▲15.0%
−1.87
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+120.1%

39.5mn → 87.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$0.0K

−100.0% YoY in FY25.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−157.7R&D−21.0SG&A−178.7Op income16.2Tax & other−162.5Net income

Margin trend · direction beats level
00000%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
217,835.0157,697.0124,517.086,140.082,274.051,100.0▲26.6%+32.5%
Selling, general & admin
34,939.021,001.017,741.018,821.024,714.020,391.0▲18.4%+0.7%
Total operating expenses
252,774.0178,698.0142,258.0104,961.0106,988.071,491.0▲25.6%+25.7%
Operating incomefeeds ROC rank
−252,774.0−178,698.0−142,258.0−104,961.0−106,988.0−71,491.0▼25.6%—
Other income, net
16,825.016,247.012,784.08,306.02,201.0395.0——
Pretax income
−235,949.0−162,451.0−129,474.0−96,655.0−104,787.0−71,096.0▼25.5%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−235,949.0−162,451.0−129,474.0−96,655.0−104,787.0−71,096.0▼25.5%—
Per share
Diluted EPSbuyback-sensitive
−2.37−1.87−2.20−2.14−2.62−1.80▲15.0%—
Diluted shares (mn)
101.0987.0158.7445.2540.0039.52▲48.1%+21.8%
Margins
† TTM = trailing four quarters through 2026-09-30.
FY18 – FY20 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-16 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.